Physician profile
Patrick Webster
NPI 1548792849
$1,821.81
in general payments reported to CMS, 2019-2025
11 companies · $586 in 2025
The $586 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $224 · 2023: $238 · 2024: $775 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279 · Education: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.85 |
| Education | $318.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $784.36 | 2022-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $314.98 | 2024-2025 | Tavneos, Evenity, Krystexxa |
| Abbvie INC. | $303.79 | 2022-2025 | Rinvoq |
| Astrazeneca Pharmaceuticals Lp | $166.19 | 2023-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $78.63 | 2024 | Lupkynis |
| Ucb, INC. | $65.16 | 2024-2025 | Bimzelx |
| Glaxosmithkline, LLC. | $33.03 | 2024 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $29.44 | 2025 | Orencia |
| Genentech USA, INC. | $25.57 | 2024 | Xolair |
| Pfizer INC. | $15.10 | 2025 | |
| Janssen Scientific Affairs, LLC | $5.56 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.